# NeuroVenti

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/neuroventi

- Industry: Healthcare Specialists
- Headquarters: Seoul, South Korea
- Website: www.neuroventi.com
- Latest round: Seed (Jun 1, 2017)
- Investors on record: 2

## About

Based in Seoul, South Korea, and founded in 2015 and led by Shin Chan-young, NeuroVenti, Inc. operates as a medical company developing therapeutic treatments for developmental mental disorders in patients with austism spectrum. In March 2024, NeuroVenti, Inc. raised KRW 1 billion in venture funding from HLB Investment and other unspecified investors.

NeuroVenti, Inc. specializes in the development of neuroprotective and therapeutic treatment to tackle intractable neurological conditions and brain diseases. It developed NV01-A02, which is a treatment for autism treatment and focusing on phase 2 clinical trials for autism spectrum disorder treatment while providing comprehensive non-clinical research services, including candidate substance discovery, preclinical consulting assessments for central nervous system disorders. The company’s products portfolio includes a wide range of solutions for brain development disorders and integrated brain disease treatments with various neurological disease models, in vivo and in vitro efficacy assessment systems, and mechanistic studies to deliver optimal treatment outcomes.

The company plans to use the proceeds from the March 2024 funding to support clinical trials and the build-out of a new drug pipeline.

## Funding rounds

- Seed, Jun 1, 2017 — Korea Tech Incubator for Startup, Synergy IB Investment

## Investors

- Korea Tech Incubator for Startup — Seed
- Synergy IB Investment (https://capitalatlas.ai/funds/synergy-ib-investment) — Seed